{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:25:03Z","timestamp":1790036703559,"version":"4.0.1"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Rift Valley fever virus (RVFV) has been cited as a potential biological-weapon threat due to the serious and fatal disease it causes in humans and animals and the fact that this mosquito-borne virus can be lethal in an aerosolized form. Current human and veterinary vaccines against RVFV, however, are outdated, inefficient, and unsafe. We have incorporated the RVFV glycoprotein genes into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a novel RVFV vaccine. Mice vaccinated with the CAdVax-based vaccine produced potent humoral immune responses and were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector.<\/jats:p>","DOI":"10.1128\/cvi.00182-09","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T01:29:02Z","timestamp":1253755742000},"page":"1624-1632","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity"],"prefix":"10.1128","volume":"16","author":[{"given":"David H.","family":"Holman","sequence":"first","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Penn-Nicholson","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danher","family":"Wang","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Woraratanadharm","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Katherine","family":"Harr","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Maher","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch, Department of Pathology, 301 University Blvd., Galveston, Texas 77555-0609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Y.","family":"Dong","sequence":"additional","affiliation":[{"name":"GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464"},{"name":"Medical University of South Carolina, Department of Microbiology and Immunology, 171 Ashley Avenue, BSB201, Charleston, South Carolina 29403"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","volume":"36","year":"2003","unstructured":"Al-Hazmi, M., E. A. Ayoola, M. Abdurahman, S. Banzal, J. Ashraf, A. El-Bushra, A. Hazmi, M. Abdullah, H. Abbo, A. Elamin, E.-T. Al-Sammani, M. Gadour, C. Menon, M. Hamza, I. Rahim, M. Hafez, M. Jambavalikar, H. Arishi, and A. Aqeel. 2003. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin. Infect. Dis.36:245-252.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","volume":"21","year":"2003","unstructured":"Balkhy, H. H., and Z. A. Memish. 2003. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int. J. Antimicrob. Agents21:153-157.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6290"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02501-07"},{"key":"e_1_3_2_6_2","first-page":"E11","volume":"9","year":"2004","unstructured":"Bossi, P., A. Tegnell, A. Baka, F. Van Loock, J. Hendriks, A. Werner, H. Maidhof, and G. Gouvras. 2004. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro. Surveill.9:E11-E12.","journal-title":"Euro. Surveill."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","year":"2006","unstructured":"Botros, B., A. Omar, K. Elian, G. Mohamed, A. Soliman, A. Salib, D. Salman, M. Saad, and K. Earhart. 2006. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol.78:787-791.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.33.3.848-853.1981"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61591-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","year":"1985","unstructured":"Caplen, H., C. J. Peters, and D. H. Bishop. 1985. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol.66:2271-2277.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1688-1699.2006"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.1997.03550050074036","volume":"278","year":"1997","unstructured":"Christopher, G. W., T. J. Cieslak, J. A. Pavlin, and E. M. Eitzen, Jr. 1997. Biological warfare. A historical perspective. JAMA278:412-417.","journal-title":"JAMA"},{"key":"e_1_3_2_13_2","first-page":"1","volume":"10","year":"2006","unstructured":"Cohen, P. 2006. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep.10:1-5.","journal-title":"IAVI Rep."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/QAD.0b013e32830e6d6d","volume":"23","year":"2009","unstructured":"Corey, L., M. J. McElrath, and J. G. Kublin. 2009. Post-step modifications for research on HIV vaccines. AIDS23:3-8.","journal-title":"AIDS"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jmv.1890240205","volume":"24","year":"1988","unstructured":"Ellis, D. S., P. V. Shirodaria, E. Fleming, and D. I. Simpson. 1988. Morphology and development of Rift Valley fever virus in Vero cell cultures. J. Med. Virol.24:161-174.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1084\/jem.62.3.433","volume":"62","year":"1935","unstructured":"Francis, T., Jr., and T. P. Magill. 1935. Rift Valley fever: a report of three cases of laboratory infection and the experimental transmission of the disease to ferrets. J. Exp. Med.62:433-448.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_17_2","first-page":"89","volume":"29","year":"2000","unstructured":"Frank-Peterside, N. 2000. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine-TSI-GSD 200. Afr. J. Med. Med. Sci.29:89-92.","journal-title":"Afr. J. Med. Med. Sci."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","volume":"357","year":"2007","unstructured":"Gerrard, S. R., and S. T. Nichol. 2007. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology357:124-133.","journal-title":"Virology"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/rmv.494","volume":"16","year":"2006","unstructured":"Goncalves, M. A., and A. A. de Vries. 2006. Adenovirus: from foe to friend. Rev. Med. Virol.16:167-186.","journal-title":"Rev. Med. Virol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","volume":"366","year":"2007","unstructured":"Gorchakov, R., E. Volkova, N. Yun, O. Petrakova, N. S. Linde, S. Paessler, E. Frolova, and I. Frolov. 2007. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology366:212-225.","journal-title":"Virology"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.virol.2008.12.011","volume":"385","year":"2009","unstructured":"Habjan, M., N. Penski, V. Wagner, M. Spiegel, A. K. Overby, G. Kochs, J. T. Huiskonen, and F. Weber. 2009. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology385:400-408.","journal-title":"Virology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/j.vaccine.2008.02.053","volume":"26","year":"2008","unstructured":"Holman, D. H., D. Wang, N. U. Raja, M. Luo, K. M. Moore, J. Woraratanadharm, N. Mytle, and J. Y. Dong. 2008. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine26:2627-2639.","journal-title":"Vaccine"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00330-06"},{"key":"e_1_3_2_24_2","first-page":"95","volume":"69","year":"2002","unstructured":"Hunter, P., B. J. Erasmus, and J. H. Vorster. 2002. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res.69:95-98.","journal-title":"Onderstepoort J. Vet. Res."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.3.826-833.1988"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","volume":"116","year":"1982","unstructured":"Kark, J. D., Y. Aynor, and C. J. Peters. 1982. A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am. J. Epidemiol.116:808-820.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","volume":"346","year":"2006","unstructured":"Kobinger, G. P., H. Feldmann, Y. Zhi, G. Schumer, G. Gao, F. Feldmann, S. Jones, and J. M. Wilson. 2006. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology346:394-401.","journal-title":"Virology"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.15.9694-9701.2005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","volume":"58","year":"1997","unstructured":"Morrill, J. C., C. A. Mebus, and C. J. Peters. 1997. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res.58:1104-1109.","journal-title":"Am. J. Vet. Res."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","volume":"53","year":"1995","unstructured":"Muller, R., J. F. Saluzzo, N. Lopez, T. Dreier, M. Turell, J. Smith, and M. Bouloy. 1995. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg.53:405-411.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","volume":"385","year":"2009","unstructured":"Naslund, J., N. Lagerqvist, M. Habjan, A. Lundkvist, M. Evander, C. Ahlm, F. Weber, and G. Bucht. 2009. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology385:409-415.","journal-title":"Virology"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","volume":"18","year":"1999","unstructured":"Pittman, P. R., C. T. Liu, T. L. Cannon, R. S. Makuch, J. A. Mangiafico, P. H. Gibbs, and C. J. Peters. 1999. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine18:181-189.","journal-title":"Vaccine"},{"key":"e_1_3_2_33_2","first-page":"6927","volume":"82","year":"2003","unstructured":"Raviprakash, K., D. Wang, D. Ewing, D. H. Holman, K. Block, J. Woraratanadharm, L. Chen, C. Hayes, J. Y. Dong, and K. Porter. 2003. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J. Virol.82:6927-6934.","journal-title":"J. Virol."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0076-6879(02)46075-2","volume":"346","year":"2002","unstructured":"Rubinchik, S., J. S. Norris, and J. Y. Dong. 2002. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol.346:529-547.","journal-title":"Methods Enzymol."},{"key":"e_1_3_2_35_2","first-page":"167","volume":"76","year":"2003","unstructured":"Rubinchik, S., J. Woraratanadharm, J. Schepp, and J. Y. Dong. 2003. Improving the transcriptional regulation of genes delivered by adenovirus vectors. Methods Mol. Med.76:167-199.","journal-title":"Methods Mol. Med."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00070-07"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","year":"1989","unstructured":"Schmaljohn, C. S., M. D. Parker, W. H. Ennis, J. M. Dalrymple, M. S. Collett, J. A. Suzich, and A. L. Schmaljohn. 1989. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology170:184-192.","journal-title":"Virology"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0812.020195","volume":"8","year":"2002","unstructured":"Shoemaker, T., C. Boulianne, M. J. Vincent, L. Pezzanite, M. M. Al-Qahtani, Y. Al-Mazrou, A. S. Khan, P. E. Rollin, R. Swanepoel, T. G. Ksiazek, and S. T. Nichol. 2002. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg. Infect. Dis.8:1415-1420.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/bjo.64.5.366","volume":"64","year":"1980","unstructured":"Siam, A. L., J. M. Meegan, and K. F. Gharbawi. 1980. Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt. Br. J. Ophthalmol.64:366-374.","journal-title":"Br. J. Ophthalmol."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2008.12","volume":"16","year":"2008","unstructured":"Singh, N., A. Pandey, L. Jayashankar, and S. K. Mittal. 2008. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther.16:965-971.","journal-title":"Mol. Ther."},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4049\/jimmunol.62.2.213","volume":"62","year":"1949","unstructured":"Smithburn, K. C., A. F. Mahaffy, et al. 1949. Rift Valley fever; accidental infections among laboratory workers. J. Immunol.62:213-227.","journal-title":"J. Immunol."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00431-07"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0042-6822(89)90171-2","volume":"169","year":"1989","unstructured":"Takehara, K., M. K. Min, J. K. Battles, K. Sugiyama, V. C. Emery, J. M. Dalrymple, and D. H. Bishop. 1989. Identification of mutations in the M RNA of a candidate vaccine strain of Rift Valley fever virus. Virology169:452-457.","journal-title":"Virology"},{"key":"e_1_3_2_44_2","unstructured":"Code of federal regulations title 21"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.043"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","volume":"52","year":"1997","unstructured":"Vialat, P., R. Muller, T. H. Vu, C. Prehaud, and M. Bouloy. 1997. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res.52:43-50.","journal-title":"Virus Res."},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","volume":"24","year":"2006","unstructured":"Wallace, D. B., C. E. Ellis, A. Espach, S. J. Smith, R. R. Greyling, and G. J. Viljoen. 2006. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine24:7181-7189.","journal-title":"Vaccine"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2006.05.033","volume":"353","year":"2006","unstructured":"Wang, D., M. Hevey, L. Y. Juompan, C. M. Trubey, N. U. Raja, S. B. Deitz, J. Woraratanadharm, M. Luo, H. Yu, B. M. Swain, K. M. Moore, and J. Y. Dong. 2006. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology353:324-332.","journal-title":"Virology"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.6.2738-2746.2006"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3201\/eid0802.010023","volume":"8","year":"2002","unstructured":"Woods, C. W., A. M. Karpati, T. Grein, N. McCarthy, P. Gaturuku, E. Muchiri, L. Dunster, A. Henderson, A. S. Khan, R. Swanepoel, I. Bonmarin, L. Martin, P. Mann, B. L. Smoak, M. Ryan, T. G. Ksiazek, R. R. Arthur, A. Ndikuyeze, N. N. Agata, and C. J. Peters. 2002. An outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg. Infect. Dis.8:138-144.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_51_2","first-page":"401","volume":"82","year":"2007","unstructured":"World Health Organization. 2007. Outbreak news. Rift Valley fever, Sudan. Wkly. Epidemiol. Rec.82:401-402.","journal-title":"Epidemiol. Rec."},{"key":"e_1_3_2_52_2","first-page":"417","volume":"82","year":"2007","unstructured":"World Health Organization. 2007. Outbreak news. Rift Valley fever, Sudan-update. Wkly. Epidemiol. Rec.82:417-418.","journal-title":"Wkly. Epidemiol. Rec."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.20.10780-10789.2003"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00182-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00182-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T18:49:01Z","timestamp":1710614941000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00182-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1128\/CVI.00182-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00182-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"2009-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-09-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}